Patents by Inventor Aaron Nilsen
Aaron Nilsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230167065Abstract: The present invention provides synthetic methods and novel intermediates in the preparation of 3-aryl Endochin-like quinolone (ELQ) compounds.Type: ApplicationFiled: May 10, 2021Publication date: June 1, 2023Applicants: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans AffairsInventors: Sovitj Pou, Rolf W. Winter, Michael K. Riscoe, J. Stone Doggett, Aaron Nilsen
-
Publication number: 20220395500Abstract: Small molecule activators of interferon regulatory factor (IRF), such as IRF3, and methods of use are provided. In particular, compositions and methods for upregulating interferon regulatory factor 3 (IRF3) activity, such as in the brain following stroke to provide potent protection against ischemic brain injury, to improve a therapeutic time window for providing treatments to stroke patients and/or for enhancement of vaccine platforms are disclosed.Type: ApplicationFiled: May 4, 2021Publication date: December 15, 2022Inventors: Susan Stevens, Mary Stenzel-Poore, Marie Foss, Aaron Nilsen, Haihong Jin
-
Publication number: 20220289690Abstract: The present invention provides compounds useful as mitochondrial permeability transition pore (mtPTP) inhibitors, the compounds being of Formula (I), or a pharmaceutically acceptable salt thereof wherein R1 is selected from the group of H, halogen, and C1-C3 alkyl; and R2 is selected from the group of H, CF3, and halogen; with the proviso that at least one of R1 and R2 is halogen or CF3.Type: ApplicationFiled: July 24, 2020Publication date: September 15, 2022Applicant: Oregon Health & Science UniversityInventors: Michael Cohen, Michael Forte, Justina Sileikyte, Aaron Nilsen, Jordan Devereaux, Paolo Bernardi
-
Publication number: 20200157053Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.Type: ApplicationFiled: January 22, 2020Publication date: May 21, 2020Inventors: Michael Riscoe, Aaron Nilsen, Allison Stickles, Galen Miley, Rolf Winter, Sovitj Pou, Yuexin Li, Jane Xu Kelly, Isaac Forquer, J. Stone Doggett, Igor Bruzual, Lisa Frueh, Rozalia Dodean, Martin Smilkstein, Holland Alday, Dennis Koop, Lisa Bleyle
-
Patent number: 10584098Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.Type: GrantFiled: August 23, 2018Date of Patent: March 10, 2020Assignee: Oregon Health & Science UniversityInventors: Michael Riscoe, Aaron Nilsen, Galen Miley, Rolf Winter, Sovitj Pou, Jane Xu Kelly, Rozalia Dodean
-
Patent number: 10532983Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.Type: GrantFiled: July 20, 2016Date of Patent: January 14, 2020Assignee: Oregon Health & Science UniversityInventors: Michael Riscoe, Aaron Nilsen, Galen Miley, Rolf Winter, Sovitj Pou, Jane Xu Kelly, Rozalia Dodean
-
Publication number: 20190389802Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.Type: ApplicationFiled: August 23, 2018Publication date: December 26, 2019Inventors: Michael Riscoe, Aaron Nilsen, Allison Stickles, Galen Miley, Rolf Winter, Sovitj Pou, Yuexin Li, Jane Xu Kelly, Isaac Forquer, J. Stone Doggett, Igor Bruzual, Lisa Frueh, Rozalia Dodean, Martin Smilkstein, Holland Alday, Dennis Koop, Lisa Bleyle
-
Patent number: 10457682Abstract: Disclosed are small molecules and pharmaceutical compositions comprising them that can be used in treating diseases associated with the major histocompatibility complex (MHC) molecule MR1.Type: GrantFiled: October 20, 2017Date of Patent: October 29, 2019Inventors: David Lewinsohn, Melanie Harriff, Aaron Nilsen, Haihong Jin, Erin Adams, Cara Froyd, Curtis McMurtrey, William Hildebrand
-
Publication number: 20180362465Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.Type: ApplicationFiled: August 23, 2018Publication date: December 20, 2018Inventors: Michael Riscoe, Aaron Nilsen, Allison Stickles, Galen Miley, Rolf Winter, Sovitj Pou, Yuexin Li, Jane Xu Kelly, Isaac Forquer, J. Stone Doggett, Igor Bruzual, Lisa Frueh, Rozalia Dodean, Martin Smilkstein, Holland Alday, Dennis Koop, Lisa Bleyle
-
Publication number: 20180273536Abstract: Disclosed are small molecules and pharmaceutical compositions comprising them that can be used in treating diseases associated with the major histocompatibility complex (MHC) molecule MR1.Type: ApplicationFiled: October 20, 2017Publication date: September 27, 2018Applicants: OREGON HEALTH & SCIENCE UNIVERSITY, HE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: David Lewinsohn, Melanie Harriff, Aaron Nilsen, Haihong Jin, Erin Adams, Cara Froyd, Curtis McMurtrey, William Hildebrand
-
Patent number: 10023538Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: GrantFiled: February 23, 2017Date of Patent: July 17, 2018Assignees: The United States of America as represented by the Department of Veterans Affairs, Oregon Health and Science UniversityInventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Publication number: 20180009760Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: ApplicationFiled: February 23, 2017Publication date: January 11, 2018Applicants: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Publication number: 20170146519Abstract: Disclosed are small molecules capable of activating the type I interferon (IFN) response by way of the transcription factor IFN regulatory factor 3 (IRF3) were identified. A high throughput in vitro screen yielded 4-(2-chloro-6-fluorobenzyl)-N-(furan-2-ylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (referred to herein as G10), which was found to trigger IRF3/IFN-associated transcription in human fibroblasts. To define cellular proteins essential to elicitation of the antiviral activity by the compound a reverse genetics approach that utilized genome editing via CRISPR/Cas9 technology was employed. This allowed the identification of IRF3, the IRF3-activating adaptor molecule STING, and the IFN-associated transcription factor STAT1 as required for observed gene induction and antiviral effects.Type: ApplicationFiled: November 21, 2016Publication date: May 25, 2017Applicant: OREGON HEALTH & SCIENCE UNIVERSITYInventors: Victor DeFilippis, Tina Sali, Kara Pryke, Jinu Abraham, Andrew Liu, Iris Archer, Kayla Sheridan, Aaron Nilsen, Rebecca Broeckel, Jessica Smith, Lisi Amsler, Daniel Streblow, Andrew Placzek
-
Publication number: 20170022164Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.Type: ApplicationFiled: July 20, 2016Publication date: January 26, 2017Inventors: Michael Riscoe, Aaron Nilsen, Allison Stickles, Galen Miley, Rolf Winter, Sovitj Pou, Yuexin Li, Jane Xu Kelly, Isaac Forquer, J. Stone Doggett, Igor Bruzual, Lisa Frueh, Rozalia Dodean, Martin Smilkstein, Holland Alday, Dennis Koop, Lisa Bleyle
-
Publication number: 20160340313Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: ApplicationFiled: December 21, 2015Publication date: November 24, 2016Applicants: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Patent number: 9249103Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: GrantFiled: January 14, 2013Date of Patent: February 2, 2016Assignees: Oregon Health & Science University, The United States of America as Represented by the Department of Veterans AffairsInventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Patent number: 9206131Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: GrantFiled: October 16, 2013Date of Patent: December 8, 2015Assignees: Oregon Health & Science University, The Department of Veterans Affairs, Medicines for Malaria Venture, University of South FloridaInventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Publication number: 20140350048Abstract: Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed.Type: ApplicationFiled: January 14, 2013Publication date: November 27, 2014Inventors: Michael K. Riscoe, Rolf W. Winter, Sovitj Pou, David J. Hinrichs, Jane Xu Kelly, Yuexin Li, Aaron Nilsen
-
Publication number: 20140045888Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: ApplicationFiled: October 16, 2013Publication date: February 13, 2014Applicants: Oregon Health & Science University, Medicines for Malaria Venture, University of South Florida, The Government of the United States of America dba The Department of Veterans AffairsInventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan
-
Patent number: 8598354Abstract: Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R2 is methyl or haloalkyl; R4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R3 is aliphatic, aryl, aralkyl, or alkylaryl; and R5, R6, R7 and R8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO2R10, wherein R10 is H, alkyl, amino or haloalkyl; provided that in formula I, R5 and R7 are not both H or R6 is not H or methoxy; and in formula II that if R4 is carbonyldioxy then R7 is not methoxy.Type: GrantFiled: June 3, 2011Date of Patent: December 3, 2013Assignees: University of South Florida, Medicines for Malaria VentureInventors: Michael K. Riscoe, Jane X. Kelly, Rolf W. Winter, David J. Hinrichs, Martin J. Smilkstein, Aaron Nilsen, Jeremy Burrows, Dennis Kyle, Roman Manetsch, Richard M. Cross, Andrii Monastyrskyi, David L. Flanigan